OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

13 Projects | 9 Researchers | $3,804,721 Invested

2020

Massachusetts General Hospital (P)

Martin Zhang

Molecular neuroimaging of RIPK1/necroptosis in Alzheimer's disease

  • Funding Amount: $206,836
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Neuroinflammation
  • Status: Closed

2019

Massachusetts General Hospital (P)

Emiliano Santarnecchi

Non-Invasive Brain Stimulation for Gamma Induction and Cognitive Enhancement in FTD

  • Funding Amount: $1,723,828
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Status: Active

2015

Massachusetts General Hospital (P)

Jacob Hooker, PhD

Epigenetic mechanisms in human memory: quantification by non-invasive PET imaging in the aged brain

  • Funding Amount: $400,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Epigenetics
  • Status: Closed

2015

Massachusetts General Hospital (P)

Neil Vasdev, PhD

Translation of an optimized PET radiopharmaceutical for imaging tau pathology in Alzheimer's patients

  • Funding Amount: $331,805
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Tau
  • Status: Closed

2013

Massachusetts General Hospital (P)

Deborah Blacker

Alzheimers Disease Modifiable Risk Database

  • Funding Amount: $25,000
  • Organization Type: Academic/Nonprofit
  • Program: Prevention
  • Status: Closed

2012

Massachusetts General Hospital (P)

Neil Vasdev, PhD

Radiopharmaceutical Development for Imaging Metabotropic Glutamate Subtype 5 Receptors (mGluR5) in AD patients with PET

  • Funding Amount: $175,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2007

Massachusetts General Hospital (P)

Tara Spires-Jones, DPhil

Sirtuins as modifiers of neurodegeneration in a mouse model of frontotemporal dementia

  • Funding Amount: $85,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2006

Massachusetts General Hospital (P)

Jack Rogers, PhD

Alzheimer's Drugs to APP translation and alpha secretase coactivation

  • Funding Amount: $97,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2003

Massachusetts General Hospital (P)

Jack Rogers, PhD

Small Molecule Drug Discovery Targeted To The Alzheimer's APP-mRNA 5' Untranslated Region

  • Funding Amount: $98,518
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2002

Massachusetts General Hospital (P)

Dora Kovacs, PhD

Effect of ACAT Inhibition on A-Beta Levels in PS1-APP Transgenic Mice

  • Funding Amount: $125,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed